GSK and Pfizer agree market leading joint venture
GlaxoSmithKline and Pfizer have agreed to combine their consumer health businesses to create a market leading joint venture with sales of around £9.8bn. The companies expect to divest assets to cover the cash cost of the integration.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: